February 9, 2017
Forward Pharma cashes in Biogen’s $1.25 billion
Forward Pharma has received $ 1.25 billion due to the settlement with Biogen’s subsidiaries, it made in January.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
February 9, 2017
Regeneron full year, quarter income up, global Praluent full year sales jump from $11M to $116M
The fourth quarter of 2016, global net sales of Praluent were $41 million, compared to $7 million in the fourth quarter of 2015.
February 9, 2017
Pulmonary drug delivery devices market to reach $43.05 billion by 2024
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
February 9, 2017
Ablynx to present RA research data at CRA Annual Scientific Meeting
Ablynx will present additional data from the Phase IIb RA combination study of its anti-IL-6R Nanobody, vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association, being held from 8-11 February 2017 in Ottawa, Ontario (Canada).
February 9, 2017
Oxford BioTherapeutics appoints chairman, adds to the board
Oxford BioTherapeutics has appointed Bernd Seizinger as Chairman, and and Jean-Pierre Bizzari, M.D. as a non-executive director, calling it a significant strengthening of its oncology focused board.
February 9, 2017
PrEP Biopharm’s asthma study misses goal, but gives useful insights
PrEP Biopharm’s study of its drug, earlier confirmed helpful for influenza and human rhinoviruse (HRV), has been undertaken to test its efficacy of the people with asthma, and check for different dosage, showed varying results.
February 9, 2017
Amryt’s first full year as a public company, Cathal Friel leaves board
Amryt’s non-executive director Cathal Friel will step down from the board the last day of March 2017, the orphan diseases focused pharmaceutical company said Thursday.
February 9, 2017
Boiron buys Laboratoire Ferrier
Boiron has signed an agreement with Laboratoires Arkopharma to take over Laboratoire Ferrier, a subsidiary of Laboratoires Arkopharma.
February 8, 2017
Bayer’s and Janssen R&D’s cardiac drug meets primary goals sooner then expected
Bayer’s and Janssen R&D’s drug for cardiac situations has already met its primary goals in the early third phase of testing, the companies said today, which concludes the testing.
February 8, 2017
Allergan’s revenue up, plans launching nine products this year
Allergan’s net revenue for the fourth quarter 2016 rose 7 percent to $3.86 billion, mostly driven by better sales of Botox, Linzess and certain other new products.